Department of Pathology, The State University of New York at Stony Brook, Stony Brook, NY, 11794, USA.
Exp Hematol Oncol. 2012 May 14;1(1):12. doi: 10.1186/2162-3619-1-12.
Hematopoietic stem cells (HSCs) are rare cells that have the unique ability to self-renew and differentiate into cells of all hematopoietic lineages. The expansion of HSCs has remained an important goal to develop advanced cell therapies for bone marrow transplantation and many blood disorders. Over the last several decades, there have been numerous attempts to expand HSCs in vitro using purified growth factors that are known to regulate HSCs. However, these attempts have been met with limited success for clinical applications. New developments in the HSC expansion field coupled with gene therapy and stem cell transplant should encourage progression in attractive treatment options for many disorders including hematologic conditions, immunodeficiencies, and genetic disorders.
造血干细胞(HSCs)是一种稀有细胞,具有自我更新和分化为所有造血谱系细胞的独特能力。HSCs 的扩增一直是开发用于骨髓移植和许多血液疾病的先进细胞疗法的重要目标。在过去的几十年中,人们已经尝试了使用已知可调节 HSCs 的纯化生长因子在体外扩增 HSCs,但这些尝试在临床应用中收效甚微。HSC 扩增领域的新发展,加上基因治疗和干细胞移植,应该会为许多疾病的治疗选择带来进展,包括血液状况、免疫缺陷和遗传疾病。